MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.
The company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.
The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.
An Australian team developed a decision model for testing asymptomatic relatives of patients with dilated cardiomyopathy to assess the cost effectiveness of testing.
The organizations provided a list of genes they believe are informative in treatment of myeloid disorders and suggested several changes to the coverage policy.
APEX-seq builds on a proteomic labelling technique and offers a new spatial genomics tool for looking at the life of transcripts within the cell.
Under the determination, which will become final following publication in Germany's Federal Gazette, Oncotype DX becomes the only multigene test nationally reimbursed in Germany for its target population early-stage breast cancer patients.
MGI and Karolinska's Centre for Translational Microbiome Research will work together to investigate the role of the microbiome in human health.
The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.
The investment bank cited management confidence in US and European test growth as meriting the upgrade, which was necessary to maintain a current $72 price target on the firm's stock.
The firm is developing a portable, rapid MDx platform for infectious disease testing in clinics, and anticipates launching a first product in 2020.
Reanalyzing clinical exomes from 2011 to 2013 increased molecular diagnostic yields significantly, leading to clinical management changes, in some cases.
Interpace Diagnostics' ThyGeNext and ThyraMir thyroid cancer assays are now covered for about 2.5 million patients in Philadelphia and Southeastern Pennsylvania.
McKesson will be the exclusive distributor of the QiaStat-Dx system in US hospitals with fewer than 200 beds and non-exclusive distributor for future expansion into retail pharmacy clinics.
The new grant will be used to conduct whole-exome sequencing on 1,000 children participating in an autism spectrum disorder study for the purposes of biomarker development.
Genome-wide association analyses spanning 26 phenotypes in diverse populations revealed new risk variants and population-specific contributions for known SNPs.
The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.
Predictive Laboratories will use Thermo Fisher reproductive health products to research the genetic basis of infertility, aiming to develop better diagnostic tools.
The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
The drug is for first-line maintenance therapy after BRCA-mutated advanced ovarian cancer patients respond to platinum chemo and the test will identify those with BRCA mutations.
The center will use Qiagen Clinical Insight to analyze, interpret, and report molecular screening of cancer patients to help identify targeted therapies and clinical trial options.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.